Last update 19 Jun 2024
ZG-005
Last update 19 Jun 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Related
9
Clinical Trials associated with ZG-005A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
ZG005联合依托泊苷及顺铂在晚期神经内分泌癌患者中的安全性、药代动力学特征及初步疗效的I/II期临床研究
[Translation] Phase I/II clinical study on the safety, pharmacokinetic characteristics and preliminary efficacy of ZG005 combined with etoposide and cisplatin in patients with advanced neuroendocrine carcinoma
A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
100 Clinical Results associated with ZG-005
Login to view more data
100 Translational Medicine associated with ZG-005
Login to view more data
100 Patents (Medical) associated with ZG-005
Login to view more data
100 Deals associated with ZG-005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Neuroendocrine Carcinoma | Phase 2 | CN | 24 May 2024 | |
| Advanced Cervical Carcinoma | Phase 2 | CN | 18 Mar 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 15 Jun 2022 | |
| Solid tumor | Phase 2 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
CTR20220021 (ASCO2024) Manual  | Early Phase 1 | 57 | rgjifrmgql(bzgauorspk) = zukoihpwsy hlgrcmrtgr (mrdyuhcxli ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | rgjifrmgql(bzgauorspk) = xvbxiwblmq hlgrcmrtgr (mrdyuhcxli ) View more | ||||||
CTR20220021 (ASCO2023) Manual | Phase 1 | 16 | htvkzmaelo(hbacssnncm) = rcrdwinybh wrlcpebmet (lbbzolibwq ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free